Literature DB >> 26838172

Hyperintense perilesional edema in the brain on T1-weighted images: Cavernous malformation or metastatic melanoma? Three case reports and literature review.

Nicolae Sarbu1, Teresa Pujol2, Laura Oleaga2.   

Abstract

Hyperintense perilesional edema in brain masses on T1-weighted images (T1WI) is an unusual radiological finding. We report three cases showing this particular type of edema, one representing cerebral hemorrhagic cavernous malformation (CCM, cavernoma) and the other two, metastases of melanoma. The association between this sign and cavernoma was recently recognized. On the other hand, in melanotic lesions, the relationship with T1WI-hyperintense perilesional edema has not yet been described. Despite being an infrequent sign, it can considerably narrow the differential diagnosis, which gives it a high value for clinical practice. Moreover, given the high prevalence of the entities that manifest this imaging feature, it can be occasionally noticed.
© The Author(s) 2016.

Entities:  

Keywords:  Cerebral cavernous malformation; cavernoma; hyperintense edema on T1; melanoma

Mesh:

Year:  2016        PMID: 26838172      PMCID: PMC4978347          DOI: 10.1177/1971400915626430

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  11 in total

Review 1.  A variety of appearances of malignant melanoma in the head: a review.

Authors:  E J Escott
Journal:  Radiographics       Date:  2001 May-Jun       Impact factor: 5.333

2.  Cerebral cavernous malformations: spectrum of neuroradiological findings.

Authors:  J J Cortés Vela; L Concepción Aramendía; F Ballenilla Marco; J I Gallego León; J González-Spínola San Gil
Journal:  Radiologia       Date:  2011-12-24

3.  Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis.

Authors:  Daniel T Ginat; Steven P Meyers
Journal:  Radiographics       Date:  2012 Mar-Apr       Impact factor: 5.333

4.  Radiographic features of tumefactive giant cavernous angiomas.

Authors:  P Kan; M Tubay; A Osborn; S Blaser; W T Couldwell
Journal:  Acta Neurochir (Wien)       Date:  2007-12-10       Impact factor: 2.216

5.  The metastatic microenvironment: brain-residing melanoma metastasis and dormant micrometastasis.

Authors:  Sivan Izraely; Orit Sagi-Assif; Anat Klein; Tsipi Meshel; Galia Tsarfaty; Metsada Pasmanik-Chor; Clara Nahmias; Pierre-Olivier Couraud; Eugene Ateh; Joseph L Bryant; Dave S B Hoon; Isaac P Witz
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

6.  Familial versus sporadic cavernous malformations: differences in developmental venous anomaly association and lesion phenotype.

Authors:  T A Petersen; L A Morrison; R M Schrader; B L Hart
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-15       Impact factor: 3.825

7.  A T1 hyperintense perilesional signal aids in the differentiation of a cavernous angioma from other hemorrhagic masses.

Authors:  T J Yun; D G Na; B J Kwon; H G Rho; S-H Park; Y-L Suh; K-H Chang
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-26       Impact factor: 3.825

8.  Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases.

Authors:  Tawny Hung; Jason Morin; William R Munday; Ian R A Mackenzie; Claire Lugassy; Raymond L Barnhill
Journal:  Am J Dermatopathol       Date:  2013-08       Impact factor: 1.533

9.  The natural history of familial cavernous malformations: results of an ongoing study.

Authors:  J M Zabramski; T M Wascher; R F Spetzler; B Johnson; J Golfinos; B P Drayer; B Brown; D Rigamonti; G Brown
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

10.  Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.

Authors:  Rustam Al-Shahi Salman; Julie M Hall; Margaret A Horne; Fiona Moultrie; Colin B Josephson; Jo J Bhattacharya; Carl E Counsell; Gordon D Murray; Vakis Papanastassiou; Vaughn Ritchie; Richard C Roberts; Robin J Sellar; Charles P Warlow
Journal:  Lancet Neurol       Date:  2012-01-31       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.